Crizotinib Targets ALK-Driven Cancers
Really exciting and encouraging results in a phase 1 clinical trial for a pill, Crizotinib, in children with Neuroblastoma!
Read the full article: Crizotinib Targets ALK-Driven Cancers in Pediatric Trial
More information on recent gene mutation research
More information regarding the recent research from Memorial-Sloan Kettering regarding the link between a gene mutation and Neuroblastoma. Click here to watch a video and find out more.
Gene Mutations Linked to Age at Neuroblastoma Diagnosis
Researchers at Memorial Sloan-Kettering Cancer Center discover a link between Neuroblastoma diagnosis and a gene mutation. There is hope in the fight for a cure! Read the article here.
60 Minutes Video: The Power of Love
A video demonstrating the bravery of families facing up to a disease like neuroblastoma.
Update from the Neuroblastoma Cancer Conference
The following is a brief summary of some of the insights I gained from the Neuroblastoma convention I attended in Chicago a few weeks ago.
There are two types of cancer: dumb and smart. A dumb cancer has only one malfunctioning gene and therefore only one gene has to be turned on or off. Dr. Brian Druker has taken advantage of this phenomenon by using a product called Gleevec to turn off only one gene in chronic myelogenous leukemia (CML). As a result, CML has almost been eliminated.